Results of Intravesical Chemo-Hyperthermia in High-risk Non-muscle Invasive Bladder Cancer

Ekin, Rahmi Gökhan; Akarken, İlker; Çakmak, Özgür; Tarhan, Hüseyin; Çelik, Orçun; İlbey, Yusuf Özlem; Divrik, Rauf Taner; Zorlu, Ferruh

doi:10.7314/apjcp.2015.16.8.3241

Cited by 18 publications

(30 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over recent decades, there has been an increasing interest in the employment of hyperthemia at 40̊C and above in the treatment of malignant tumors (13,16,(18)(19)(20). Hyperthermia may increase chemotherapeutic drug uptake, influence the intracellular distribution and metabolism of drugs, and/or inhibit repair of DNA damage in neoplastic cells, thus, improving the effect of chemotherapeutic agents (13,16,20).…”

Section: Introductionmentioning

confidence: 99%

“…Hyperthermia may increase chemotherapeutic drug uptake, influence the intracellular distribution and metabolism of drugs, and/or inhibit repair of DNA damage in neoplastic cells, thus, improving the effect of chemotherapeutic agents (13,16,20). Mitomycin C (MMC) as an alkylating cytostatic agent is commonly used to treat NMIBC.…”

Section: Introductionmentioning

confidence: 99%

“…Bladder intracavitary hyperthermic perfusion chemotherapy (BHPC), the combination of local hyperthermia with chemotherapy, can significantly improve the effect of intracavity chemotherapy, and is reported to have an additive or supra-additive effect, preventing NMIBC recurrence post-TUR (13)(14)(15)(16)(18)(19)(20). However, these previous conventional trials were based on hot water-, microwave-or radiofrequency-induced local hyperthermia, either individually or in combination with cytostatic agents, which could maintain continuous and stable treatment temperatures, but lack effective temperature control or regulation, and cannot provide uniform distribution of heat to the bladder.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection

Cui

Wang

et al. 2017

Oncology Reports

View full text Add to dashboard Cite

Abstract. Preventing the recurrence of non-muscle invasive bladder cancer (NMIBC) post-transurethral resection (TUR) remains challenging. The aim of the present study was to investigate the effectiveness and safety of bladder intracavitary hyperthermic perfusion chemotherapy (BHPC) for prevention of NMIBC recurrence post-TUR. Between December 2006 and December 2014, 53 patients with NMIBC who underwent TUR were randomly assigned to receive BHPC (BHPC group, 28 patients) or intravesical chemotherapy alone (chemotherapy group, 25 patients) at the Intracelom Hyperthermic Perfusion Therapy Center of Guangzhou Medical University Cancer Hospital (Guangzhou, China). BHPC was performed by combining perfusion-based hyperthermia with chemotherapeutic agent mitomycin C (MMC) in the bladder, and the chemotherapy group of patients received bladder MMC perfusion. The concentration of MMC in the perfusion fluid and serum were assessed at different time-points. Tumor recurrence, disease-free survival (DFS), and side-effects were recorded and compared between the 2 groups. Results revealed that BHPC was performed smoothly, at ~44̊C in the bladder cavity. Patients tolerated BHPC, and no side-effects were observed. Both BHPC and intravesical chemotherapy achieved a high MMC concentration in the bladder perfusion liquid, but low MMC concentration in the serum, although serum MMC concentrations in the BHPC group were significantly higher (P<0.05). The tumor recurrence rate was significantly lower (10.7 vs. 28.0%; P=0.02) and the DFS period was significantly longer (37±1.2 vs. 19±0.9 months; P=0.001) in the BHPC group than in the chemotherapy group. Our results demonstrated that BHPC is safe and effective for preventing NMIBC recurrence post-TUR and prolongs DFS.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection

Cui

Wang

et al. 2017

Oncology Reports

View full text Add to dashboard Cite

show abstract

“…After the ninth treatment session the patient developed abdominal pain and was diagnosed with a perforation of the posterior wall. It was not reported whether the perforation was caused by the catheter placement or due to the treatment itself [14,31].…”

Section: Unithermiamentioning

confidence: 99%

“…Ekin et al evaluated the efficacy of CHT in patients with high-risk NMIBC [31]. Forty-three patients who underwent CHT were evaluated retrospectively.…”

Section: Unithermia Systemmentioning

confidence: 99%

Chemohyperthermia in non-muscle-invasive bladder cancer: An overview of the literature and recommendations

Liem

Crezee

Rosette

et al. 2016

International Journal of Hyperthermia

View full text Add to dashboard Cite

Non-muscle-invasive bladder cancer (NMIBC) is characterised by a high risk of recurrence for the present standard treatment of transurethral resection of the bladder (TURB) followed by intravesical instillation of Mitomycin-C (MMC) or bacillus Calmette-Gu erin (BCG). To decrease this high recurrence rate, alternative treatments are studied. Intravesical MMC combined with hyperthermia could be an interesting alternative active treatment for intermediate-and high-risk NMIBC, and has been investigated in the past years. Hyperthermia, raising tumour temperatures to 40-44 C, can be achieved with several hyperthermia systems, based on three different techniques: 1) intravesical microwave induced heating, 2) conductive heating, and 3) loco-regional, using external radiofrequency antennas. In this review an overview is given of the available hyperthermia systems and the reported outcomes. Future directions are discussed. Optimal implementation of a combined regimen of MMC and hyperthermia requires further clinical trials to identify patients who will benefit most from this treatment, to optimise treatment schedules and to compare the efficacy of different hyperthermia devices. ARTICLE HISTORY

show abstract

Hyperthermic MMC—A Systematic Review

Goonewardene

Persad

Motiwala

et al. 2019

Management of Non-Muscle Invasive Bladder Cancer

View full text Add to dashboard Cite

Results of Intravesical Chemo-Hyperthermia in High-risk Non-muscle Invasive Bladder Cancer

Cited by 18 publications

References 14 publications

Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection

Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection

Chemohyperthermia in non-muscle-invasive bladder cancer: An overview of the literature and recommendations

Hyperthermic MMC—A Systematic Review

Contact Info

Product

Resources

About